Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

BLOOD CANCER JOURNAL

NATURE PUBLISHING GROUP

1. NCATS NIH HHS [UL1 TR000371] Funding Source: Medline
2. NCI NIH HHS [CA180858, UG1 CA189971, U10 CA021076, R01 CA201634, CA180835, P50 CA142509, U10 CA180835, CA189971, U10 CA180821, U10 CA021115, U10 CA031946, CA31946, U10 CA180819, CA180888, CA189830, U10 CA180820, U10 CA032102, U10 CA180799, CA180819, CA21076, CA180799, U10 CA180888, UG1 CA189830, U10 CA180858, CA21115, CA180821, CA180820] Funding Source: Medline